Tempus AI, Inc. - Class A Common Stock (TEM)

These 10 large-cap stocks gained this week, some due to positive news such as media rights deals or FDA approvals.

Donald Trump has accused Nancy Pelosi of trading on "inside information" after her portfolio's returns outperformed the S&P 500 in 2025.

Stocks continued to rise despite conflicting inflation data; the trend is still bullish, but investors should expect volatility heading into September

Ark Invest has six main ETFs with several around for more than 10 years. A look at the top 10 holdings across the six funds and what it could mean.

Tempus AI fired on all cylinders in Q2, and Morgan Stanley upgraded the stock. What is the near and long-term outlook for this name, up 89% in 2025?

Second-quarter results arrived with numbers that caused investors to feel increasingly bullish.

Tempus AI Inc (TEM) reported strong Q2 2025 results, beating revenue and EPS estimates with 89.6% YoY growth. Stock surged 8.7% pre-market on raised guidance and AI-driven expansion.

Tempus AI beat Q2 estimates with 90% revenue growth, narrowed losses, and a raised 2025 outlook driven by strong genomics and data services gains.

This week, from August 4th to August 10th, 2025, marks a busy period in the second-quarter earnings season, with hundreds of companies across various sectors scheduled to report their financial results. These earnings calls are crucial events for investors, analysts, and the broader market, as they provide insights into corporate

Although shares have retreated from their all-time high, those who bought shares one year ago are still looking at growth in their positions.

Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.

AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.

On Wednesday, Cathie Wood-led Ark Invest executed significant trades, including substantial purchases in Tempus AI Inc. (NASDAQ:TEM), NVIDIA Corp. (NASDAQ:NVDA), 3iQ Ether Stakin

Tempus AI Inc (NASDAQ:TEM) shares are trading higher Wednesday after the company announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ejection fraction software.

On Thursday, Cathie Wood-led Ark Invest made significant trades involving Tempus AI Inc. (NASDAQ:TEM), Coinbase Global Inc. (NASDAQ:COIN), Robinhood Markets Inc. (NASDAQ